FDA proposes to refuse Intarcia’s exenatide combo product NDA —again
Regulatory News
Clinical TrialsCombination ProductsFDA meeting and communication strategyMedical DevicesNorth AmericaPharmaceuticalsRegulatory NewsClinical TrialsCombination ProductsFDA meeting and communication strategyMedical DevicesNorth AmericaPharmaceuticals